SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

OpenAI admits its AI agents used a wiki as a springboard for rogue behavior

Anthropic pushes back IPO as investors await one of AI’s biggest public-market tests

The biggest opportunity is not in AI infrastructure. It's in applications.

More AI agents can mean more work for humans

Buzz

Most popular

Daily

Weekly

1

ServiceNow acquires Israeli AI startup Sweep in deal estimated at hundreds of millions

2

Palo Alto’s CEO invested in the startup his company just bought for $500 million

3

Proofpoint in talks to acquire Israeli cybersecurity company Varonis

4

Wonderful raises $550 million at $5 billion valuation just six months after $2 billion round

5

Upwind raises $300 million, more than doubles valuation to $3.8 billion in five months

CytoReason

4 stories about CytoReason

דוד הראל מייסד מנכ"ל CytoReason

CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models

17.07.24|Meir Orbach

The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.

מייסדי סייטוריזן, מימין: דוד הראל, פרופ' שי שן-אור, אלינה סטרוסבצקי, רנו גוז'ו

CytoReason raises $20 million from Pfizer for AI drug discovery and development platform

20.09.22|Meir Orbach

Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years

David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro

This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development

בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason

10.01.19|Lilach Baumer

Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars